VITAL MEDICINES NOT AVAILABLE: NATIONAL AND INTERNATIONAL REGULATION ANALYSIS, UPDATE PROPOSAL OF NATIONAL LIST

Authors

  • Gloria A. SANDOVAL
  • Claudia P. VACCA G
  • Jorge OLARTE

DOI:

https://doi.org/10.17533/udea.vitae.769

Keywords:

orphan drugs, exceptional drugs, rare disease, neglected disease, legislation

Abstract

A comparative revision was carried out on the national and international policies and regulations about

access of orphan and/or vital drugs.. An analysis of: orphan drugs´ list from USA, European Union

and all applications for importation of not available drugs submitted by the Drug Regulatory Authority

(INVIMA) until 2006; an informal consultation with health care providers, insurance companies and

distributors of vital medicines, were included, in order to improve the actual vital drugs list within the

frame of public health programs. The analysis included all drugs that have been protected by Decree

2085 from 2002, as well as the imported drugs by the Ministry of Social Welfare under the public

health program. 26 of 107 proposed drugs match the lists of orphan drugs from the countries analyzed

and 12 are protected with exclusivity by decree 2085 from 2002.

|Abstract
= 375 veces | PDF (ESPAÑOL (ESPAÑA))
= 308 veces|

Downloads

Download data is not yet available.

Published

16-02-2009

How to Cite

SANDOVAL, G. A., VACCA G, C. P., & OLARTE, J. (2009). VITAL MEDICINES NOT AVAILABLE: NATIONAL AND INTERNATIONAL REGULATION ANALYSIS, UPDATE PROPOSAL OF NATIONAL LIST. Vitae, 15(1). https://doi.org/10.17533/udea.vitae.769

Issue

Section

Pharmaceutical Care